FLNA
Filana Therapeutics, Inc.
NASDAQ: FLNA · HEALTHCARE · BIOTECHNOLOGY
$1.20
-5.71% today
Updated 2026-06-05
Market cap
$63.77M
P/E ratio
—
P/S ratio
2.54x
EPS (TTM)
$-1.61
Dividend yield
—
52W range
$1 – $5
Volume
0.4M
WallStSmart proprietary scores
38
out of 100
Grade: D
Sell
Investment rating
4.3
Growth
C4.8
Quality
C3.0
Profitability
D4.7
Valuation
C2/9
Piotroski F-Score
Weak
-7.0
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$6.50
+441.67%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Piotroski 2/9 — weak financial health
- Altman Z -6.97 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-8.88M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-76.25M | $-97.22M | $-24.34M | $-90.97M | $-10.33M |
| EPS | — | — | — | — | $-1.61 |
| Free cash flow | $-80.23M | $-82.44M | $-117.03M | $-32.83M | $-8.88M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Filana Therapeutics, Inc. trades at $1.20. Our Smart Value Score of 38/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -6.97, it sits in the distress.
Frequently asked questions
What is Filana Therapeutics, Inc.'s stock price?
Filana Therapeutics, Inc. (FLNA) trades at $1.20, on a P/S of 2.5x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Filana Therapeutics, Inc. overvalued?
Filana Therapeutics, Inc. carries a Smart Value Score of 38/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Filana Therapeutics, Inc. (FLNA)?
The 12-month analyst consensus target is $6.50, about 441.7% above the current $1.20. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Filana Therapeutics, Inc.'s Altman Z-Score is -6.97, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio2.54x
ROE-114.32%
Beta-0.78
50D MA$1.52
200D MA$2.35
Shares out0.05B
Float0.05B
Short ratio—
Avg volume0.4M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—